1421687-39-9

Basic information

• Product Name: 5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-3-hydrazinylpyridazine
• Synonyms: 5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-3-hydrazinylpyridazine
• CAS NO: 1421687-39-9
• Molecular Weight: 394.907
• Mol File: 1421687-39-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-3-hydrazinylpyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-3-hydrazinylpyridazine(1421687-39-9)
• EPA Substance Registry System: 5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-3-hydrazinylpyridazine(1421687-39-9)

Safety Data

• Hazardous Substances Data: 1421687-39-9(Hazardous Substances Data)

Upstream product

• 1421687-38-8 3-chloro-5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)pyridazine 
• 1274804-87-3 4’-chloro-2-iodomethyl-biphenyl 
• 159430-52-1 5-(1-piperazinyl)-3(2H)-pyridazinone 
• 1421687-37-7 5-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)pyridazin-3(2H)-one 

Downstream Products

• 1421687-40-2 7-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-amine 
• 1421687-41-3 tert-butyl (7-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)carbamate 
• 1421687-51-5 tert-butyl (7-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)((4-fluoro-3-nitrophenyl)sulfonyl)carbamate 
• 1421687-42-4 N-(7-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)-4-fluoro-3-nitrobenzenesulfonamide 
• 1421687-30-0 C₄₀H₄₃ClN₁₀O₄S₂ 

Relevant articles and documents

The Role of the acidity of N-heteroaryl sulfonamides as inhibitors of Bcl-2 family protein-protein interactions

Overexpression of the antiapoptotic members of the Bcl-2 family of proteins is commonly associated with cancer cell survival and resistance to chemotherapeutics. Here, we describe the structure-based optimization of a series of N-heteroaryl sulfonamides t